Pulmonary embolism cost-effectiveness of therapy: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pulmonary embolism}} | {{Pulmonary embolism}} | ||
'''Editor(s)-In-Chief:''' {{ATI}}, [[C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com]; | '''Editor(s)-In-Chief:''' {{ATI}}, [[C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com]; {{AE}} {{Rim}} | ||
==Overview== | ==Overview== | ||
When indicated, early discharge and outpatient treatment for pulmonary embolism | When indicated, early discharge and outpatient treatment for pulmonary embolism is more cost effective than inpatient treatment.<ref name="pmid16162764">{{cite journal| author=Aujesky D, Smith KJ, Cornuz J, Roberts MS| title=Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. | journal=Chest | year= 2005 | volume= 128 | issue= 3 | pages= 1601-10 | pmid=16162764 | doi=10.1378/chest.128.3.1601 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16162764 }} </ref> The inpatient treatment with [[low molecular weight heparin]] has been reported to be more cost effective than that with [[unfractionated heparin]].<ref name="pmid16162764">{{cite journal| author=Aujesky D, Smith KJ, Cornuz J, Roberts MS| title=Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism. | journal=Chest | year= 2005 | volume= 128 | issue= 3 | pages= 1601-10 | pmid=16162764 | doi=10.1378/chest.128.3.1601 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16162764 }} </ref> | ||
==References== | ==References== | ||
Revision as of 20:39, 11 July 2014
|
Pulmonary Embolism Microchapters |
|
Diagnosis |
|---|
|
Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores |
|
Treatment |
|
Follow-Up |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Pulmonary embolism cost-effectiveness of therapy On the Web |
|
Pulmonary embolism cost-effectiveness of therapy in the news |
|
Directions to Hospitals Treating Pulmonary embolism cost-effectiveness of therapy |
|
Risk calculators and risk factors for Pulmonary embolism cost-effectiveness of therapy |
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
When indicated, early discharge and outpatient treatment for pulmonary embolism is more cost effective than inpatient treatment.[1] The inpatient treatment with low molecular weight heparin has been reported to be more cost effective than that with unfractionated heparin.[1]
References
- ↑ 1.0 1.1 Aujesky D, Smith KJ, Cornuz J, Roberts MS (2005). "Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism". Chest. 128 (3): 1601–10. doi:10.1378/chest.128.3.1601. PMID 16162764.